BC
ABMD

Broadfin Capital’s Abiomed Inc ABMD Stock Holding History

Broadfin Capital’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-100,000
Closed -$6.57M – 99
2015
Q2 		$6.57M Buy
+100,000
New +$6.64M 0.35% 63

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital's ABMD Position: Q3 2015 in Review

Broadfin Capital sold out of Abiomed Inc (ABMD) in Q3 2015, closing a stake of 100,000 shares — an estimated $6.57M sold.

Broadfin Capital first reported a position in ABMD in Q2 2015 and held it in 1 quarter. The position peaked at $6.57M in Q2 2015. 243 funds tracked by Wall St. Rank hold ABMD as of Q3 2015.

  • Broadfin Capital reported no remaining Abiomed Inc position as of Q3 2015 after selling out during the quarter.
  • Broadfin Capital sold 100,000 Abiomed Inc shares in Q3 2015, an estimated $6.57M.
  • Broadfin Capital first reported a position in Abiomed Inc in Q2 2015 and held it in 1 quarter.
  • Broadfin Capital's Abiomed Inc position peaked at $6.57M in Q2 2015.
  • 243 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2015.

Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.